Searched for
PHARMACEUTICAL POLICY INDIA
India’s nutraceutical market set to nearly double to $57 billion by 2030 on preventive health boomIndia's health-conscious population is fueling a boom in the nutraceutical market, projected to nearly double to $55-57 billion by 2030. Th...- Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...
- World MSME Day: Chemical industry seeks policy support to boost competitiveness amid global trade disruptionsIndian chemical industry leaders are urging a policy overhaul to boost competitiveness ahead of World MSME Day 2026. They highlight the nee...
- Strong balance sheets help India Inc absorb West Asia fallout: CrisilA stress test by Crisil Ratings covering 34 sectors that account for 65% of its rated corporate debt suggests that India Inc remains broadl...
- Why is market rising today? Sensex soars 800 pts, Nifty above 24,250. 3 key factors powering D-St bullsIndian stock markets experienced a significant surge on Thursday, with both the Sensex and Nifty climbing over 1%. This bullish trend was f...
- Sensex jumps over 700 points, Nifty rises above 24,200 as oil prices cool below $73 per barrelOn Thursday, Indian stock markets experienced a remarkable surge, with both Sensex and Nifty seeing significant gains as oil prices fell be...
- Forget power: The unquenchable AI thirst propelling water stocks up to 45%India's water sector is experiencing a surge, with stocks like Shakti Pumps and VA Tech Wabag jumping up to 45% in a month. This rally is f...
- Why did market rise today? Sensex rallied 791 pts, Nifty closed above 24,000; 6 key factors drove D-St reboundIndian stock markets witnessed a significant surge today, with Sensex and Nifty climbing up to 1%. This positive momentum was fueled by the...
- Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...
- Drugmakers yet to see gains from government's minimum import price policyGovernment's Minimum Import Price (MIP) initiative to boost domestic drug makers faces a slow start. Despite setting price thresholds for k...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- India, Russia prevented global economy from collapsing: IMEMO chiefRussia and India have forged a new global economic model, preventing global collapse and aiding the Global South with affordable resources....
- India’s trade strategy: Moving beyond FTAsCurrently, India’s FTA utilisation rate hovers around 25% compared to 70-80% in developed economies.
- Share of services in exports rises to 48.8% in FY26India's services exports have seen significant growth. The services sector now accounts for nearly half of the country's total exports. Thi...
- India's structural growth story remains strong despite global uncertainties: VenturaIndia's long-term growth outlook remains robust despite global geopolitical uncertainties and intermittent market volatility, supported by ...
- IT rebound may lack legs, outlook remains cautious: Sunil SinghaniaSpeaking at the ET NOW Markets Summit 2026, Singhania said that although valuations in the sector have become more reasonable after the sha...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
Load More
